BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Pre-Mkt 05-08 07:07:03 EDT

1.09

-0.02

-1.80%

High1.15	Low1.09	Vol87.34K
Open1.12	D1 Closing1.11	Amplitude5.41%
Mkt Cap11.93M	Tradable Cap4.42M	Total Shares10.94M
T/O98.04K	T/O Rate2.16%	Tradable Shares4.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":1.09,"timestamp":1778184000000,"preClose":1.11,"halted":0,"volume":87338,"delay":0,"changeRate":-0.018018018018018032,"floatShares":4052600,"shares":10940400,"eps":-1.234148,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"05-08 07:07:03 EDT","open":1.12,"high":1.15,"low":1.09,"amount":98038.5993572,"amplitude":0.054054,"askPrice":1.21,"askSize":100,"bidPrice":1.06,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-1.234148,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778247000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.09,"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.09,"latestTime":"19:18 EDT","volume":5205,"amount":5706.4046,"timestamp":1778195895700,"change":0.02,"changeRate":0.018349,"amplitude":0.018349},"volumeRatio":1.6580289222094067,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA","defaultTab":"news","newsList":[{"id":"2631573773","title":"BioCardia CEO Peter Altman acquires 5,000 common shares for $5,550","url":"https://stock-news.laohu8.com/highlight/detail?id=2631573773","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631573773?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:41","pubTimestamp":1777506078,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman bought 5,000 common shares at USD 1.11.Altman beneficially owned 280,766 common shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLc6t23n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires 5,000 common shares for $5,550","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630302389","title":"BioCardia Gains Japanese Patent for Heart3D Imaging Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2630302389","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630302389?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:40","pubTimestamp":1777380042,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has shared an announcement. On April 28, 2026, BioCardia announced that Japanese authorities had allowed a patent titled “Tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-gains-japanese-patent-for-heart3d-imaging-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-gains-japanese-patent-for-heart3d-imaging-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630016183","title":"BioCardia says Japan allows patent for Heart3D fusion imaging software","url":"https://stock-news.laohu8.com/highlight/detail?id=2630016183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630016183?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:06","pubTimestamp":1777377983,"startTime":"0","endTime":"0","summary":"BioCardia announced allowance of a Japanese patent covering its Heart3D Fusion Imaging software used for planning and real-time navigation during CardiAMP cell therapy procedures.Patent, titled “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation,” adds intellectual property protection for Heart3D in Japan.Claims cover fusing preoperative 3D CT or MRI heart images with two orthogonal 2D images to generate a 3D model for procedure guidance and location recording.BioCardia said it is working toward submissions in Japan for CardiAMP cell therapy and Helix intramyocardial delivery system following consultations with Japanese regulators.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL1krgLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630090663","title":"BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3d™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During Cardiamp Cell Therapy Procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2630090663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630090663?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:00","pubTimestamp":1777377605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUABDRH57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629073201","title":"BioCardia CEO Peter Altman buys $1,230 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629073201","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629073201?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:05","pubTimestamp":1776891912,"startTime":"0","endTime":"0","summary":"BioCardia President, CEO, director Peter Altman reported open-market purchases of 1,000 common shares at a weighted average price of USD 1.23.Altman’s direct beneficial ownership rose to 275,766 common shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL5x0TWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman buys $1,230 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725083","title":"BioCardia reports ‘positive’ outcome in consult with Japan’s PMDA for CardiAMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725083","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628725083?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:09","pubTimestamp":1776690575,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) reported a positive outcome in its formal clinical consultation with Japan’s Pharmaceutical and Medical Device Agency, PMDA. PMDA ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-reports-positive-outcome-in-consult-with-japans-pmda-for-cardiamp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-reports-positive-outcome-in-consult-with-japans-pmda-for-cardiamp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174020","title":"BioCardia says Japan PMDA deems CardiAMP data sufficient for market clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174020","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174020?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:03","pubTimestamp":1776686614,"startTime":"0","endTime":"0","summary":"Japan PMDA determined U.S. clinical safety and efficacy data for BioCardia CardiAMP Cell Therapy in ischemic heart failure is likely sufficient to support market clearance.Consultation aligned on acceptability of foreign clinical data, intended patient indications, post-marketing study expectations in Japan.BioCardia expects PMDA minutes to set feedback and timing for a potential regulatory filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL36ppff:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU2095319765.USD","BK4139","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","SG9999014021.USD","BK4585","LU2210149790.SGD","NDAQ","IE00BN0W2T93.GBP","BCDA","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230927","title":"BioCardia gets Nasdaq notice for failing $2.5 million stockholders’ equity rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230927","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230927?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:32","pubTimestamp":1776285167,"startTime":"0","endTime":"0","summary":"Nasdaq issued BioCardia a noncompliance notice on April 10, 2026 for failing to meet Nasdaq Capital Market minimum stockholders’ equity requirement under Listing Rule 5550.Stockholders’ equity totaled $895,000 as of Dec. 31, 2025 versus $2.5 million minimum.Nasdaq could grant up to 180 days from April 10, 2026 to regain compliance if plan is accepted.Common stock continues to trade on Nasdaq Capital Market under symbol BCDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL89TLFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624020855","title":"BioCardia Inc - Expects FDA Meeting This Quarter Under Breakthrough Designation for Cardiamp System","url":"https://stock-news.laohu8.com/highlight/detail?id=2624020855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624020855?lang=en_us&edition=fundamental","pubTime":"2026-04-02 22:11","pubTimestamp":1775139094,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA5S1C1P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624650431","title":"BioCardia Inc - Submits Cardiamp HF Clinical Study Data to FDA - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624650431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624650431?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:19","pubTimestamp":1775135955,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501169","title":"BioCardia seeks FDA meeting on accelerated approval pathway for CardiAMP in heart failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501169","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624501169?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:02","pubTimestamp":1775134965,"startTime":"0","endTime":"0","summary":"BioCardia filed a request for an FDA meeting to discuss an accelerated approval pathway for CardiAMP System in ischemic heart failure with reduced ejection fraction.Company submitted CardiAMP HF clinical study data to FDA under its Breakthrough Device designation.BioCardia aims to obtain FDA feedback this quarter on a proposed approval submission based on safety data from 125 ischemic HFrEF patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL2lNJ7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623348309","title":"Press Release: Tamboran Farmout Pilot Area and BCDA Acreage for Significant Premium in Acreage Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2623348309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623348309?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:57","pubTimestamp":1774875420,"startTime":"0","endTime":"0","summary":"--  Tamboran Resources and Formentera Partners , the owner of. Daly Waters Energy, LP , have executed a Farm-in Agreement (Farm-in. Agreement) to advance development of the Beetaloo Basin in Australia's. --  Under the Farm-in Agreement, Tamboran will farm down approximately. 10,000 acres of its working interest across the Shenandoah North Pilot. and the Beetaloo Central Development Area  to DWE.--  The Farm-in Agreement provides for a staged earn-in, up to US$28.5. --  The agreement follows DWE announcing a strategic joint venture with. --  The transaction recognizes the value premium that can be realised on. Beetaloo acreage as it is defined and matured, like the Pilot Area, as. well as the value that can be realised for adjacent appraisal areas, like. \"The additional investment supports local jobs, infrastructure development and long--term energy security for the Northern Territory, while keeping us firmly on track for first gas in the third quarter of 2026. We are pleased to be prog","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","TBN","BK4588","BK4213","BK4585","VDE","TBN.AU","BK7142","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622952800","title":"Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622952800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622952800?lang=en_us&edition=fundamental","pubTime":"2026-03-28 13:00","pubTimestamp":1774674050,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCardia (BCDA) and Nkarta (NKTX) with bullish sent...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biocardia-bcda-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biocardia-bcda-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4588","NKTX","BK4139","BK4505","HCSG","XBI","LU0128526141.USD","BCDA","XLV","BK4581","BK4137","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622890512","title":"BioCardia President and CEO Peter Altman acquires common shares; purchases total $1,110","url":"https://stock-news.laohu8.com/highlight/detail?id=2622890512","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622890512?lang=en_us&edition=fundamental","pubTime":"2026-03-27 08:06","pubTimestamp":1774569979,"startTime":"0","endTime":"0","summary":"BioCardia reported open-market purchases of common stock by Peter Altman, President and CEO and a director.Altman acquired 900 shares at prices of USD 1.24 and USD 1.22.Following the transactions, he beneficially owned 274,766 shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL1VX8BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia President and CEO Peter Altman acquires common shares; purchases total $1,110","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622907302","title":"Alliance Global Partners Sticks to Their Buy Rating for BioCardia (BCDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622907302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622907302?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:16","pubTimestamp":1774440971,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on BioCardia, with a price target of $6.00. Molloy c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-their-buy-rating-for-biocardia-bcda-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-their-buy-rating-for-biocardia-bcda-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622016685","title":"BioCardia Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622016685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622016685?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:38","pubTimestamp":1774388301,"startTime":"0","endTime":"0","summary":"BioCardia Inc reports results for the quarter ended December 31 - Earnings SummaryBioCardia Inc BCDA.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended December 31, highe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C2WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013835","title":"BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013835","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013835?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:13","pubTimestamp":1774383237,"startTime":"0","endTime":"0","summary":"BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.17) by 64.71 percent. This is a 76 percent increase over losses of $(0.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51444648/biocardia-q4-eps-0-06-beats-0-17-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622018271","title":"Press Release: BioCardia Reports 2025 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622018271","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622018271?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:05","pubTimestamp":1774382700,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., March 24, 2026  -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission.The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are provided below.CardiAMP autologous cell therapy in ischemic heart failure of reduced ejection fraction . In parallel to advancing the regulatory discussions with the USA FDA and Japan PMDA on the potential market release of the CardiAMP System for the treatment of ischemic heart failure, we are advancing the confirmatory CardiAMP HF II Trial.clinical study began at University of Wisconsin at Madison and Henry Ford. Health System in Detroit MI, respectively. Emory Univers","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4604","R","TM","BK4099","BK4232","BK4139","BCDA","BK4588","BK4022","BK4555","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738459","title":"BioCardia Inc  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738459","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738459?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:35","pubTimestamp":1774006505,"startTime":"0","endTime":"0","summary":"BioCardia Inc  expected to post a loss of17cents a share - Earnings Preview BioCardia Inc BCDA.OQ BCDA.O is expected to  show no change in quarterly revenue when it reports  results on March 24 for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277414","title":"BioCardia Inc. to host 2025 financial results and corporate update conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277414","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277414?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:48","pubTimestamp":1773964086,"startTime":"0","endTime":"0","summary":"BioCardia will host a financial results and corporate update conference call on March 24, 2026 at 4:30 PM EDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4qsTsP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","SG9999014039.USD","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4588","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","BCDA","BK4585","NDAQ","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0439},{"period":"1month","weight":-0.084},{"period":"3month","weight":-0.128},{"period":"6month","weight":-0.1615},{"period":"1year","weight":-0.5887},{"period":"ytd","weight":-0.128}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.022375},{"month":4,"riseRate":0.375,"avgChangeRate":0.007226},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.079635},{"month":6,"riseRate":0.25,"avgChangeRate":-0.048165},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016411},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction